Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Submits HPV Tests to FDA

NEW YORK (GenomeWeb News) – Third Wave Technologies said today that it has submitted to the US Food and Drug Administration applications for clearance of two molecular tests for human papillomavirus.
 
The Madison, Wis.-based firm submitted data from trials on its 14-type high-risk HPV and 16/18 genotyping tests. The submissions come after last month’s announcement that the clinical trials on the two tests met their primary endpoints.
 
Third Wave intends to have an instrument on the market next year for the HPV tests, it said in a statement.
 
Third Wave said the global HPV testing market is projected to be $250 million in 2008. But the firm, and Qiagen, which sells the only FDA-cleared molecular test for HPV, believe the market is highly underpenetrated and could be valued at around $1 billion.
The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.